A lung disease, an unfamiliar target and a molecule designed by machines: Insilico Medicine has taken its AI discovery experiment into Phase III. The clever part is how it pays for the long wait.

Before Scott Gies cofounded Zoe Biosciences, he studied genomes, octopus cognition and marine conservation. The connecting idea is simple: follow the evidence, even when it takes the scenic route.

From a Stryker unit in Iraq to smartphone diagnostics, text-first primary care and a newly acquired Seattle startup, Younggren has spent two decades asking the same practical question: how much closer can the system move to the person who needs it?